RxDoctor Payments Data

Sippora Lehrhaupt

Physician Assistant · Rockville, MDNPI 1720262009

Payments from drug & device makers

$4,398in general payments, 2019–2025

Across 269 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$543
  • Pfizer$310
  • Astellas Pharma US Inc$243
  • Lilly USA, LLC$219
  • Merck$168
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,37599%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,398 in reported general payments places this provider in the 90th percentile of 2,567 physician assistant providers in Maryland.

See all physician assistant providers in Maryland

Medicare billing

Part B allowed, 2024
$41,088
Medicare patients
119
Services billed
549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide34$37,947
OzempicSemaglutide29$28,748
VeozahFezolinetant12$6,490
Olmesartan Medoxomil39$691
Duloxetine Hcl18$661
Albuterol Sulfate HfaAlbuterol Sulfate16$626
Levothyroxine Sodium64$572
Pravastatin Sodium19$442
Metoprolol Succinate23$415
SynthroidLevothyroxine Sodium15$408
Atorvastatin Calcium49$397
Amlodipine Besylate51$386
Buspirone Hcl17$364
ValacyclovirValacyclovir Hcl12$352
Rosuvastatin Calcium36$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$219$37,94734 claims
Novo NordiskOzempic$543$28,74829 claims
Astellas Pharma US IncVeozah$243$6,49012 claims
AbbVieSynthroid$1,230$40815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,567 physician assistant providers in Maryland.

Other physician assistant in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →